| Feb 27, 2026 |
Mar 2, 2026 |
JENKINS GEORGE M
|
Director |
Buy |
85.0
|
+4,000
|
2.03%
|
✗
|
$500K |
| Feb 27, 2026 |
Mar 2, 2026 |
HERON ELAINE J
|
Director |
Buy |
90.0
|
+2,400
|
4.68%
|
✗
|
$300K |
| Feb 18, 2026 |
Feb 20, 2026 |
Goin Kathleen
|
COO |
Sell |
10.0
|
-4,302
|
-100.00%
|
✓
|
$341.6K |
| Feb 5, 2026 |
Feb 9, 2026 |
Martini Jeffrey S
|
Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 5, 2026 |
Feb 9, 2026 |
Kline Ashley Hartmann
|
Chief Commercial Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 5, 2026 |
Feb 9, 2026 |
Kaupinen Wes
|
CEO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 5, 2026 |
Feb 9, 2026 |
Korenberg Matthew E
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 5, 2026 |
Feb 9, 2026 |
Goin Kathleen
|
COO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jan 21, 2026 |
Jan 23, 2026 |
Goin Kathleen
|
COO |
Sell |
10.0
|
-4,302
|
-100.00%
|
✓
|
$420K |
| Dec 17, 2025 |
Dec 19, 2025 |
Goin Kathleen
|
COO |
Sell |
7.5
|
-4,302
|
-100.00%
|
✓
|
$415K |
| Nov 19, 2025 |
Nov 21, 2025 |
Goin Kathleen
|
COO |
Sell |
7.5
|
-4,302
|
-100.00%
|
✓
|
$371K |
| Jun 10, 2025 |
Jun 11, 2025 |
Wessel Tadd S.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 10, 2025 |
Jun 11, 2025 |
KIRITSY CHRISTOPHER P
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 10, 2025 |
Jun 11, 2025 |
JENKINS GEORGE M
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 10, 2025 |
Jun 11, 2025 |
HERON ELAINE J
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 10, 2025 |
Jun 11, 2025 |
Davis Todd C
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| May 27, 2025 |
Jun 3, 2025 |
Kline Ashley Hartmann
|
Chief Commercial Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Jun 3, 2025 |
Kline Ashley Hartmann
|
Chief Commercial Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Apr 9, 2025 |
Apr 10, 2025 |
JENKINS GEORGE M
|
Director |
Buy |
87.5
|
+4,990
|
2.60%
|
✗
|
$100.8K |
| Feb 5, 2025 |
Feb 10, 2025 |
Kaupinen Wes
|
CEO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 5, 2025 |
Feb 10, 2025 |
Martini Jeffrey S
|
Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 5, 2025 |
Feb 10, 2025 |
Goin Kathleen
|
COO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 5, 2025 |
Feb 10, 2025 |
Korenberg Matthew E
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 5, 2025 |
Feb 7, 2025 |
PALVELLA THERAPEUTICS, INC.
|
Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 5, 2025 |
Feb 7, 2025 |
PALVELLA THERAPEUTICS, INC.
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 5, 2025 |
Feb 7, 2025 |
PALVELLA THERAPEUTICS, INC.
|
CEO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 5, 2025 |
Feb 7, 2025 |
PALVELLA THERAPEUTICS, INC.
|
COO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Jan 6, 2025 |
Kaupinen Wes
|
CEO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 18, 2024 |
Dec 19, 2024 |
JENKINS GEORGE M
|
Director |
Buy |
82.5
|
+4,000
|
2.13%
|
✗
|
$51.7K |
| Dec 13, 2024 |
Dec 17, 2024 |
HERON ELAINE J
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 13, 2024 |
Dec 17, 2024 |
Wessel Tadd S.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 13, 2024 |
Dec 17, 2024 |
Davis Todd C
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 13, 2024 |
Dec 17, 2024 |
Martini Jeffrey S
|
Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 13, 2024 |
Dec 17, 2024 |
Goin Kathleen
|
COO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 13, 2024 |
Dec 17, 2024 |
Korenberg Matthew E
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 13, 2024 |
Dec 17, 2024 |
JENKINS GEORGE M
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 13, 2024 |
Dec 17, 2024 |
Kaupinen Wes
|
CEO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 13, 2024 |
Dec 17, 2024 |
KIRITSY CHRISTOPHER P
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 13, 2024 |
Dec 17, 2024 |
BVF PARTNERS L P/IL
|
Other |
Neutral |
90.0
|
+438,929
|
172.69%
|
✗
|
- |
|
Dec 16, 2024 |
Korenberg Matthew E
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Dec 16, 2024 |
Wessel Tadd S.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Dec 16, 2024 |
Kaupinen Wes
|
CEO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Dec 16, 2024 |
Goin Kathleen
|
COO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Dec 16, 2024 |
Martini Jeffrey S
|
Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Dec 16, 2024 |
JENKINS GEORGE M
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Dec 16, 2024 |
Davis Todd C
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Dec 16, 2024 |
HERON ELAINE J
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Dec 16, 2024 |
Dellora Investments LP
|
Other |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Dec 12, 2024 |
Dec 12, 2024 |
GERAGHTY JAMES A
|
Director |
Sell |
27.5
|
-1
|
-100.00%
|
✗
|
$0 |
| Dec 2, 2024 |
Dec 9, 2024 |
KIRITSY CHRISTOPHER P
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Nov 18, 2024 |
Dellora Investments LP
|
10% Owner |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Aug 7, 2024 |
Oct 28, 2024 |
GERAGHTY JAMES A
|
Director |
Buy |
90.0
|
+1
|
100.00%
|
✗
|
$1 |
| Aug 9, 2024 |
Aug 12, 2024 |
ADAR1 Capital Management, LLC
|
10% Owner |
Buy |
87.5
|
+6,000
|
4.33%
|
✗
|
$92.3K |
|
Jul 31, 2024 |
ADAR1 Capital Management, LLC
|
10% Owner |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 21, 2023 |
Jun 23, 2023 |
Barbier Ann
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 21, 2023 |
Jun 23, 2023 |
GERAGHTY JAMES A
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 21, 2023 |
Jun 23, 2023 |
Kiener Peter A
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 21, 2023 |
Jun 23, 2023 |
KIRITSY CHRISTOPHER P
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 21, 2023 |
Jun 23, 2023 |
Richman Michael
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 21, 2023 |
Jun 23, 2023 |
Said Maya R.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 21, 2023 |
Jun 23, 2023 |
Sherman Matthew L
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| May 25, 2023 |
May 30, 2023 |
KIRITSY CHRISTOPHER P
|
Director |
Buy |
90.0
|
+10,000
|
100.00%
|
✗
|
$8.5K |
|
May 22, 2023 |
BVF PARTNERS L P/IL
|
10% Owner |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 24, 2023 |
Feb 28, 2023 |
Bures Thomas
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 24, 2023 |
Feb 28, 2023 |
Kaufmann Hitto
|
Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 24, 2023 |
Feb 28, 2023 |
Mousa Ahmed
|
Chief Business Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 24, 2023 |
Feb 28, 2023 |
Olwill Shane
|
Chief Development Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 24, 2023 |
Feb 28, 2023 |
Yoder Stephen S.
|
CEO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 22, 2022 |
Jun 24, 2022 |
Barbier Ann
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 22, 2022 |
Jun 24, 2022 |
Said Maya R.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 22, 2022 |
Jun 24, 2022 |
GERAGHTY JAMES A
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 22, 2022 |
Jun 24, 2022 |
Kiener Peter A
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 22, 2022 |
Jun 24, 2022 |
KIRITSY CHRISTOPHER P
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 22, 2022 |
Jun 24, 2022 |
Richman Michael
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 22, 2022 |
Jun 24, 2022 |
Sherman Matthew L
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| May 13, 2022 |
May 16, 2022 |
Demuth Tim
|
Chief Medical Officer |
Buy |
91.3
|
+6,000
|
100.00%
|
✗
|
$10.3K |
| Feb 22, 2022 |
Feb 24, 2022 |
Demuth Tim
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 22, 2022 |
Feb 24, 2022 |
Mousa Ahmed
|
Chief Business Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 22, 2022 |
Feb 24, 2022 |
Olwill Shane
|
Chief Development Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 22, 2022 |
Feb 24, 2022 |
Bures Thomas
|
CFO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 22, 2022 |
Feb 24, 2022 |
Kaufmann Hitto
|
SVP, Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Feb 22, 2022 |
Feb 24, 2022 |
Yoder Stephen S.
|
CEO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Oct 21, 2021 |
Mousa Ahmed
|
Chief Business Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Aug 30, 2021 |
Sep 1, 2021 |
Olwill Shane
|
Chief Development Officer |
Sell |
22.5
|
-38,400
|
-89.22%
|
✗
|
$196.4K |
| Aug 1, 2021 |
Aug 3, 2021 |
Demuth Tim
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Aug 3, 2021 |
Demuth Tim
|
Chief Medical Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
|
Aug 3, 2021 |
Olwill Shane
|
Chief Development Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 25, 2021 |
Jun 29, 2021 |
Sherman Matthew L
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 25, 2021 |
Jun 29, 2021 |
Said Maya R.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 25, 2021 |
Jun 29, 2021 |
Richman Michael
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 25, 2021 |
Jun 29, 2021 |
KIRITSY CHRISTOPHER P
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 25, 2021 |
Jun 29, 2021 |
Kiener Peter A
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 25, 2021 |
Jun 29, 2021 |
GERAGHTY JAMES A
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 25, 2021 |
Jun 29, 2021 |
Barbier Ann
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Mar 4, 2021 |
Mar 8, 2021 |
Bures Thomas
|
President |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Mar 4, 2021 |
Mar 8, 2021 |
Kaufmann Hitto
|
SVP, Chief Scientific Officer |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Mar 4, 2021 |
Mar 8, 2021 |
Yoder Stephen S.
|
CEO |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jul 21, 2020 |
Jul 22, 2020 |
Aquilo Capital Management, LLC
|
10% Owner |
Sell |
16.3
|
-1,900,000
|
-34.08%
|
✗
|
$5.6M |
| Jun 23, 2020 |
Jun 25, 2020 |
KIRITSY CHRISTOPHER P
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |
| Jun 23, 2020 |
Jun 25, 2020 |
Said Maya R.
|
Director |
Neutral |
52.5
|
-
|
0.00%
|
✗
|
- |